NCT05673967View on ClinicalTrials.gov

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

September 12, 2024

Study Completion Date

March 28, 2025

Conditions
Relapsed and Refractory Multiple Myeloma (RRMM)
Interventions
OTHER

Non-Interventional

No study treatment will be administered on this study.

Trial Locations (1)

10591

Regeneron Research Facility, Tarrytown

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY